

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Olejnik, et. al.
 Customer No.: 051957
 Serial No: 10/574,523
 Filed: March 30, 2006
 For: Pharmaceutical Compositions
 Comprising Alpha-2-Adrenergics And Trefoil
 factor Family Peptides

Group Art Unit: 1626
 Examiner: Havlin, Robert H.
 Confirmation No. 6986

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Commissioner for Patents
 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an Amendment to the Restriction/Election Requirement dated April 30, 2008 on the above-identified application.

[X] Amendment (6 pages)

[X] The fee has been calculated as shown below.

<i>CLAIMS</i>	<i>COLUMN A Claims Remaining After Amendment</i>	<i>COLUMN B Highest Number Previously Paid</i>	<i>COLUMN C Present Extra</i>	<i>Rate</i>	<i>Additional Fee</i>
<i>Total</i>	15	42	0	x \$50	\$.00
<i>Independent</i>	1	3	0	x \$210	\$.00
[] First Presentation of Multiple Dep. Claim x \$280 =					\$.00
[X] Time Extension Fees (2 months):					\$460.00
Total Due:					\$460.00

Please charge Deposit Account 01-0885 for any fees related to this Amendment.

Respectfully submitted,

/John E. Wurst/

John E. Wurst

Reg. No. 40,283

Attorney of Record

Date: July 14, 2008

Please send all inquiries to:
 John E. Wurst (T2-7H)
 Allergan, Inc.
 2525 Dupont Drive
 Irvine, CA 92612
 Telephone: 714/246-5475/Facsimile: 714/246-4249